SEOUL: South Korea on Thursday (Jun 30) authorised AstraZeneca PLC’s antibody-based therapy for preventing COVID-19 infection in people with a poor immune reaction, increasing its choices as it works to relieve the pandemic problem on the healthcare system.
The Ministry of Food and Drug Safety given emergency use authorisation for 20, 1000 doses of Evusheld for individuals aged 12 years and old who have not been exposed to the coronavirus.
Nearly 87 per cent of South Korea’s 52 million people are fully vaccinated against COVID-19, while sixty-five per cent have also a new booster, government data showed. However , individuals with compromised immune systems or those with a history of severe adverse reaction to vaccines may need alternative prevention choices.
Evusheld might be used for people whose immune systems are usually unlikely to attach adequate responses in order to COVID-19 vaccination or for whom vaccination is not recommended, the particular ministry said.
AstraZeneca in Mar said Evusheld maintained its neutralising action against the Omicron coronavirus variant in an self-employed study, and that it reduced the risk of symptomatic COVID-19 by seventy seven per cent in trials.
While vaccines rely on an unchanged immune system to develop focused antibodies and infection-fighting cells, Evusheld consists of laboratory-made antibodies designed to linger in the body for years to contain the pathogen in case of infection.
The British drugmaker’s therapy has already been sanctioned in the United States and its use has been recommended with the European Medicines Company.
Read more upon: https://www.channelnewsasia.com/asia/south-korea-authorises-astrazeneca-covid-19-therapy-evusheld-vulnerable-people-2782821